News
![Is AbbVie Stock a Buy Now?: https://g.foolcdn.com/editorial/images/766565/pharmacist-talking-to-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNU5FYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8fdec8eca42b75f2236f1927f67d049c6b8eb0db/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/pharmacist-talking-to-patient.jpg?locale=us)
Is AbbVie Stock a Buy Now?
Pharmaceutical giant AbbVie (NYSE: ABBV) is undergoing significant changes. Last year, the company lost U.S. patent exclusivity for its biggest cash cow, immunosuppressant Humira, and is now seeing
![Viking Therapeutics: A Teachable Moment About Investing for the Long Term: https://g.foolcdn.com/editorial/images/767179/rocket.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNVpFYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--07ef1383e404223831e9be66af026f3c6a9202d5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/rocket.jpg?locale=us)
Viking Therapeutics: A Teachable Moment About Investing for the Long Term
On Tuesday, Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech specializing in treatments for metabolic diseases, saw its stock price surge by a staggering 121% in response to a clinical
![Viking Therapeutics Just Soared 120% on Optimism About Its Weight Loss Candidate. Too Late to Buy?: https://g.foolcdn.com/editorial/images/767161/gettyimages-1226994628.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMk5FYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ccfc659a093569283a6c4226504c22072d6d5702/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1226994628.jpg?locale=us)
Viking Therapeutics Just Soared 120% on Optimism About Its Weight Loss Candidate. Too Late to Buy?
The weight loss drug market is growing in leaps and bounds -- and today the biggest winners are Eli Lilly and Novo Nordisk. These big pharma companies are bringing in billions thanks to their drugs
![CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst: https://g.foolcdn.com/editorial/images/766837/lab-research-scientists-women-in-stem.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMlpFYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--28fc368b7fccb30cf2cc098661d39c9239c1a8c7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/lab-research-scientists-women-in-stem.jpg?locale=us)
CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst
Just one day after the ascendant biotech CRISPR Therapeutics (NASDAQ: CRSP) reported its fourth-quarter earnings on Feb. 21, Chardan Capital analyst Geulah Livshits raised her price target for the
![A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now: https://g.foolcdn.com/editorial/images/766932/dna-on-monitor-scientists.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBemhFYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--51fa9a6eae1df4bdf4d1beff44dcab4b06d265ae/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dna-on-monitor-scientists.jpg?locale=us)
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now
You've no doubt seen mutual fund warnings that past performance isn't necessarily indicative of future results. This caution applies to stocks as well. However, it doesn't just mean that investments
![Is Viking Therapeutics a Buy Now?: https://g.foolcdn.com/editorial/images/767160/brilliant-scientist-with-tablet-getty.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBekpFYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--63b0d7ff6c4d29359e08d7c8b15ccd92aa98d6ee/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/brilliant-scientist-with-tablet-getty.jpg?locale=us)
Is Viking Therapeutics a Buy Now?
Shares of Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech, more than doubled recently. The market started hurling money at the stock after some mid-stage clinical trial results
EQS-News: Biotest achieves EBIT forecast for 2023
![Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Sarepta Therapeutics (NASDAQ: SRPT)Q4 2023 Earnings CallFeb 28, 2024, 4:30 p.m. ET
Operator
Source Fool.com
![Geron (GERN) Q4 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
Geron (GERN) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Geron (NASDAQ: GERN)Q4 2023 Earnings CallFeb 28, 2024, 8:00 a.m. ET
Operator
Source Fool.com
![Is It Too Late to Buy Sarepta Therapeutics Stock?: https://g.foolcdn.com/editorial/images/766349/physician-giving-a-high-five-to-a-young-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHRDYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--adf6485d3c52567cadc5cdc52c36b22f6b2837f1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-giving-a-high-five-to-a-young-patient.jpg?locale=us)
Is It Too Late to Buy Sarepta Therapeutics Stock?
Sarepta Therapeutics (NASDAQ: SRPT), a midcap biotech company, was riding high 18 months ago. The company was awaiting a crucial regulatory approval from the U.S. Food and Drug Administration (FDA)
EQS-News: Karl Lauterbach visits Biotest AG's plasma donation centre in Cologne and emphasises important contribution to patient care
![MannKind (MNKD) Q4 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
MannKind (MNKD) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
MannKind (NASDAQ: MNKD)Q4 2023 Earnings CallFeb 27, 2024, 5:00 p.m. ET
Operator
Source Fool.com
![Why Novo Nordisk and Eli Lilly Stocks Slipped Today: https://g.foolcdn.com/editorial/images/767102/medical-professional-with-hand-on-head.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMEZDYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--49b74cb58695e6f9aa30884422cd1e5984c0120e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/medical-professional-with-hand-on-head.jpg?locale=us)
Why Novo Nordisk and Eli Lilly Stocks Slipped Today
The arrival of a potential new rival in an important product category dinged the share prices of pharmaceutical companies Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) on Tuesday. Both slumped
![Pfizer Stock Has 30% Upside, According to 1 Wall Street Analyst: https://g.foolcdn.com/editorial/images/766635/doctors-with-pharmaceutical-images.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFJBYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--99c11397a0099da657821e30f40b5de293235bf1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctors-with-pharmaceutical-images.jpg?locale=us)
Pfizer Stock Has 30% Upside, According to 1 Wall Street Analyst
With Pfizer (NYSE: PFE) stock hovering near a five-year low, one analyst has just started coverage of the pharmaceutical giant and is telling investors it's time to buy. In a report released last
![Has Novavax Just Solved Its Biggest Problem?: https://g.foolcdn.com/editorial/images/766803/gettyimages-1295271909.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFpBYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d30e62d3777187a57c92f74b691506f3a062d421/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1295271909.jpg?locale=us)
Has Novavax Just Solved Its Biggest Problem?
Many investors have seen Novavax (NASDAQ: NVAX) as a promising recovery story ever since the biotech launched a plan to cut costs to better match the revenue opportunities ahead of it. Once one of
![3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow: https://g.foolcdn.com/editorial/images/766684/gettyimages-1335027284.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOUJBYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--83b5e0098012d2aec69b41afccc0625b94f724fd/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1335027284.jpg?locale=us)
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Vertex Pharmaceuticals (NASDAQ: VRTX) has built a cystic fibrosis (CF) treatment empire that brings in billions of dollars in earnings annually. And just recently, the company demonstrated it could
![1 Magnificent S&P 500 Dividend Stock Down 23% to Buy Right Now: https://g.foolcdn.com/editorial/images/766397/gettyimages-1417884809.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTQvYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8809cfa48eb94a6a50f23c92128c89fccec6ba25/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1417884809.jpg?locale=us)
1 Magnificent S&P 500 Dividend Stock Down 23% to Buy Right Now
Particular financial metrics have been proven to indicate market-beating potential when analyzing stocks. Three examples are businesses with consistently growing dividend payments and a low payout
![3 Biotech Stocks to Buy and Hold for the Next 10 Years: https://g.foolcdn.com/editorial/images/766287/doctor-with-patient-talking.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN3cvYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ecc117fbbae29b1b63da7d6344acaf54b82d6008/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-with-patient-talking.jpg?locale=us)
3 Biotech Stocks to Buy and Hold for the Next 10 Years
The biotech industry can be risky and volatile, but there are advantages to investing in companies in this field. Many of them develop lifesaving drugs, the kinds we'll need until we can completely
![Could Abbott Laboratories Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/766713/gettyimages-1188369583.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNU0vYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0e70cbd74f046ae7f8c389da625d2835fbcaf1a0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1188369583.jpg?locale=us)
Could Abbott Laboratories Stock Help You Become a Millionaire?
Abbott Laboratories (NYSE: ABT) has proven itself as a long-term winner for investors. The healthcare giant has grown earnings over time, and the shares have climbed too. In just the past year
![The Ultimate Growth Stock to Buy With $1,000 Right Now: https://g.foolcdn.com/editorial/images/766590/scientists-happy.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBejQvYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f506f3ffb03c525b60cf37a7626432344e93b96d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-happy.jpg?locale=us)
The Ultimate Growth Stock to Buy With $1,000 Right Now
My first response when thinking about the ultimate growth stock to buy with $1,000 right now was to go with a high-flying AI stock. But the more I deliberated, the less comfortable I was choosing
![1 Amazing Artificial Intelligence (AI) Stock Down 29% You'll Regret Not Buying on the Dip: https://g.foolcdn.com/editorial/images/766553/two-people-in-an-office-looking-at-a-computer-monitor-and-discussing-what-is-on-it.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMFkvYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--98a4bdbbea2b595816ef3e91b70f6c1a7c6a14ca/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-people-in-an-office-looking-at-a-computer-monitor-and-discussing-what-is-on-it.jpg?locale=us)
1 Amazing Artificial Intelligence (AI) Stock Down 29% You'll Regret Not Buying on the Dip
Cyber threats are a growing concern among the world's top businesses. Technologies like generative artificial intelligence (AI) are helping bad actors craft sophisticated attacks by creating
![This 1 Number May Ensure Nvidia's Artificial Intelligence (AI) Chip Dominance: https://g.foolcdn.com/editorial/images/766549/gettyimages-1503223319-1201x756-1cb3974.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNmsrYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--14b871e4bac482f71aa9496dbabe9d2a5035c5e8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1503223319-1201x756-1cb3974.jpg?locale=us)
This 1 Number May Ensure Nvidia's Artificial Intelligence (AI) Chip Dominance
Nvidia (NASDAQ: NVDA) stock has soared over 435% since the beginning of 2023 as companies flock to the tech giant for its top-performing suite of artificial intelligence (AI) chips. Its top and
![2 Dividend-Paying Tech Stocks to Buy Right Now: https://g.foolcdn.com/editorial/images/765948/woman-smartphone2-getty.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNVUrYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5507f1016f4d203a1c9dadac1ddf1ff243f468ce/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/woman-smartphone2-getty.jpg?locale=us)
2 Dividend-Paying Tech Stocks to Buy Right Now
The stock market is one of the greatest wealth-building tools in the world, but the short-term volatility can be a lot for some investors to stomach. Luckily, dividend stocks provide investors with
![3 Dividend Stocks That Are No-Brainer Buys Right Now: https://g.foolcdn.com/assets/images/fool/tmf-logo_400x400.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaTRFIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--7b1053a3605f66e35a9c178293b2594f08cb4204/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/tmf-logo_400x400.png?locale=us)
3 Dividend Stocks That Are No-Brainer Buys Right Now
There are well over 5,000 stocks on the market that pay dividends. It would take you years to analyze each one of them in detail. Fortunately, you don't have to exert such an effort.
Three Fool.com
![Harvard Business Professor on Failing Well: https://g.foolcdn.com/editorial/images/765894/mfm_18.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMFkrYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--87c9e68958bffada48eb7c6a181096a0c810f889/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/mfm_18.jpg?locale=us)
Harvard Business Professor on Failing Well
In this podcast, Motley Fool host Deidre Woollard talks about the art of failing with Amy Edmondson, the Novartis Professor of Leadership and Management at the Harvard Business School, and author of